Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056]

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-02-05 DOI:10.1016/j.ejca.2024.115194

A. Özkan , E. Kapiteijn , F. van den Bos , M.J.B. Aarts , F.W.P.J. van den Berkmortel , C.U. Blank , M. Bloem , W.A.M. Blokx , M.J. Boers-Sonderen , J.J. Bonenkamp , A.J.M. van den Eertwegh , J.W.B. de Groot , J.B. Haanen , C.E. Holtslag , G.A.P. Hospers , D. Piersma , R.S. van Rijn , A.M. Stevense-den Boer , K.P.M. Suijkerbuijk , A.A.M. van der Veldt , N.A. de Glas

引用次数: 0

查看原文本刊更多论文

《辅助免疫治疗在老年III期和切除IV期黑色素瘤患者中的应用：来自荷兰黑色素瘤治疗登记的毒性和无复发生存结果》的更正。[j].中国生物医学工程学报，2002,11(2):444 - 444。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.